Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6880-6888

  Li, Caixia ^a   Chen, Xiaochen ^a   Yu, Xiao ^a   Zhu, Yibei ^b   Ma, Chao ^a   Xia, Rui ^b   Ma, Jinfeng ^a   Gu, Caihong ^a   Ye, Lu ^a   Wu, Depei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Clinicopathological prognostic stratification; T cell; Tim 3; Tumor immune escape

Indexed keywords

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BLOOD; CASE CONTROL STUDY; CD4 CD8 RATIO; FEMALE; FLOW CYTOMETRY; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TUMOR ESCAPE; UPREGULATION; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CD4-CD8 RATIO; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84912120225     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D, Tao S, Zhu T, Liu Y, Yang Y, Zhou X, Zhao Y, Wu M, Wei J, Wang D, Xu G, Wang S, Ma D, Zhou J. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010; 207: 505-520.
2. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
3. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregμlation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
4. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012; 7: e30676.
5. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172-189.
6. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regμlates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252.
7. Pentcheva-Hoang T, Corse E, Allison JP. Negative regμlators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229: 67-87.
8. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimμlatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
9. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
10. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501-4510.
11. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-2213.
12. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499.
13. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, Saeed S, Benko E, Kovacs C, Kaul R, Ostrowski MA. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010; 40: 2493-2505.
14. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
15. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma pati-ents. J Clin Invest 2011; 121: 2350-2360.
16. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2013; 116: 2484-2493.